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PHeart Rhythm Disorders
acing-Induced Increase in QT
ispersion Predicts Sudden Cardiac Death
ollowing Cardiac Resynchronization Therapy
hajil Chalil, MRCP, Zaheer R. Yousef, MD, MRCP, Sarkaw A. Muyhaldeen, MRCP,
ussell E. A. Smith, MD, FRCP, Paul Jordan, FRCP, Christopher R. Gibbs, MD, MRCP,
rancisco Leyva, MD, FRCP
utton Coldfield, United Kingdom
OBJECTIVES This study was designed to determine whether cardiac resynchronization therapy (CRT) by
means of biventricular pacing (BiVP) alters the QT interval (QTc) and QT dispersion (QTD),
and whether such changes relate to the risk of developing major arrhythmic events (MAE).
BACKGROUND Prolonged QTc is associated with MAE. Left ventricular pacing and BiVP alter QTc.
METHODS A total of 75 patients with drug-resistant heart failure (New York Heart Association
functional class III/IV) and QRS duration 120 ms underwent CRT. The QTc and QTD
were measured before and 48 days after BiVP.
RESULTS Over 807 days (range 93 to 1,543 days), 11 patients had aMAE. Compared to baseline, at 48 days
after CRT, QTD increased in 47% of patients and QTc decreased in 53%. The QTc at follow-up
was higher in MAE patients compared with no-MAE patients (35.9  14.2 ms vs. 0.52  6.0
ms; p 0.0323). Similar differential responses for QTD were observed (46.4 13.5 ms in MAE
vs.5.1 4.1 ms in noMAE, p 0.0001). The MAE occurred in 29% of patients exhibiting
an increase in QTD and in 3% of those exhibiting a decrease (p  0.0017). In multiple
regression analyses, change in QTD from baseline (QTD) strongly predicted MAE,
independent of QTc, QRS duration, and left ventricular ejection fraction and end-diastolic
volume (p  0.001). Differences in survival curves were observed when patients were
dichotomized according to whether QTD increased or decreased in relation to baseline values
(p  0.0001).
CONCLUSIONS The MAE in patients with BiVP are related to pacing-induced increases in QTD. Measures
of ventricular repolarization at the time of pacemaker implantation may guide selection of
patients for combined CRT and defibrillator therapy. (J Am Coll Cardiol 2006;47:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.12.0742486–92) © 2006 by the American College of Cardiology Foundation
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the Cardiac Resynchronization Heart Failure (CARE-HF)
tudy has recently shown that in patients with heart failure
HF), cardiac resynchronization therapy (CRT) using
iventricular pacing (BiVP) leads to a 36% reduction in
ll-cause mortality (1). This study also showed that, despite
reduction in all-cause mortality, CRT did not reduce the
ate of sudden cardiac death (35% in the CRT group vs.
2% in the medical therapy group). This finding is in
eeping with a recent meta-analysis of randomized trials of
RT showing that although BiVP reduces death from
rogressive HF, death from causes other than pump failure
ay be increased (2). In this respect, it has been suggested
hat BiVP may enhance arrhythmogenicity by reversing the
ormal depolarization pattern from endocardium to epicar-
ium, which enhances transmural dispersion of repolariza-
ion and propagation of early after-repolarizations (3).
From the Department of Cardiology, Good Hope Hospital, Sutton Coldfield,
nited Kingdom. Dr. Muyhaldeen held a research fellowship sponsored by
edtronic Inc. Dr. Chalil holds a research fellowship sponsored by Medtronic Inc.
rs. Smith, Jordan, and Leyva have received sponsorship from Medtronic Inc. Dr.
eyva has received sponsorship from St. Jude Inc. The first two authors contributed
qually to this work.m
Manuscript received July 4, 2005; revised manuscript received September 7, 2005,
ccepted December 1, 2005.hese factors are known to facilitate the development of
entricular tachyarrhythmias (4,5). In this light, we hypoth-
sized that pacing-induced changes in QT interval (QTc)
nd QT dispersion (QTD) relate to the risk of sudden
ardiac death in patients undergoing CRT.
ETHODS
atients. Data presented pertains to consecutive patients
eferred to our service and undergoing successful BiVP
mplantation between October 2000 and December 2003.
he following inclusion criteria were adopted: 1) HF from
ny cause; 2) moderate-to-severe HF (New York Heart
ssociation [NYHA] functional class III or IV) despite
ptimal medical treatment; 3) QRS duration 120 ms; and
) left ventricular ejection fraction (LVEF) 35%. Exclu-
ions included: 1) contraindications to cardiac pacing;
) myocardial infarction or acute coronary syndrome within
he previous 3 months; 3) presence of or indications for an
mplantable cardioverter-defibrillator (ICD); 4) severe
tructural valvular heart disease, 5) presence of comorbidi-
ies likely to threaten survival for 12 months; and 6) pul-
onary edema requiring intravenous diuretics in the previ-
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June 20, 2006:2486–92 QT Dispersion in CRTus week. All patients gave written informed consent, and
he study was approved by the North Birmingham Ethics
ommittee.
tudy design. Patients referred for CRT underwent pace-
aker implantation during an elective admission or after
tabilization during the course of an unplanned admission
or acute decompensated HF. Patients underwent a com-
rehensive clinical assessment that included assessment of
YHA functional class; a six-min hall walk test (6); a
uality-of-life assessment using Minnesota Living with
eart Failure questionnaire (7); and transthoracic echocar-
iography on the day before implantation and at one month,
hree months, and every six months thereafter.
ajor arrhythmic events (MAE). Mortality data was
ollected through medical records and, where appropriate,
rom interviews with patients’ carers. Sudden cardiac death
as defined as “a natural, unexpected death due to cardiac
auses, heralded by an abrupt loss of consciousness within
ne hour of the onset of acute symptoms” (8). For the
urposes of this study, MAE were defined as the combined
ate of sudden cardiac death and/or resuscitation from a
otentially fatal ventricular tachyarrhythmia.
evice therapy. Transvenous biventricular pacemaker im-
lantation was undertaken using standard techniques under
ocal anaesthesia. With reference to the 45° left anterior
blique radiographic view, coronary sinus leads were posi-
ioned in the following o’clock positions: 3 (61 %), 4 (20%),
(1.7%), 6 (11.9%), 9 (15.2%), and 11 (3.4%). There were
ve cases of left ventricular (LV) lead dislodgement and no
evice failures. Patients were entered in the study only after
successful implantation and were followed up in a dedi-
ated CRT clinic. Patients in sinus rhythm (n  56)
nderwent transmitral Doppler-directed optimization of
trioventricular delay (9) before discharge and at every
cheduled visit thereafter. Backup atrial pacing was set at 60
eats/min, and the pacing mode was set to DDDR with an
nterventricular delay of 4 ms. For patients in chronic atrial
brillation (n  19), right ventricular (RV) and LV leads
Abbreviations and Acronyms
BiVP  biventricular pacing
CARE-HF  Cardiac Resynchronization Heart Failure
study
CRT  cardiac resynchronization therapy
HF  heart failure
ICD  implantable cardioverter-defibrillator
LV  left ventricle/ventricular
LVEDV  left ventricular end-diastolic volume
LVEF  left ventricular ejection fraction
LVESV  left ventricular end-systolic volume
MAE  major arrhythmic events
NYHA  New York Heart Association
QTc  rate-corrected QT interval
QTD  QT dispersion
RV  right ventricle/ventricularere implanted. In six of these cases, a standard dual- dhamber generator was used, in which the LV lead was
onnected to the “atrial” port and the RV lead to the ventricular
ort, and the generator was programmed to VVT mode with
he shortest sensed LV-to-RV delay of 30 ms. In the remain-
er of the patients with atrial fibrillation, a Medtronic
nSync III generator (model 8042) was used, plugging the
trial port and programming the generator to a ventricular
riggered mode. Generators used included the InSync mod-
ls 8040 (n  13) and 8042 (n  32) (Medtronic Inc.,
inneapolis, Minnesota), Frontier (n 7) (St. Jude Medical,
t. Paul, Minnesota), CRT 8000 (n  1) (Vitatron, Arnhem,
he Netherlands), Stratos (n  4) (Biotronik, Berlin, Ger-
any), Contak TR model 1241 (n 2) and Renewal TR2 (n
2) (Guidant Corp., Indianapolis, Indiana) and Medtronic
igma DR (n  1) (Medtronic Inc.).
lectrocardiograms (ECG) and echocardiography. Rest-
ng 12-lead ECGs were used to assess ventricular repolar-
zation. The QT intervals at baseline and 1 month (mean 48
ays) in each of the six precordial leads (V1 to V6) were
anually measured retrospectively for every patient by an
xperienced investigator blinded to the patients’ final out-
ome (10). The QTc for each lead represented the mean of
wo consecutive QTcs, measuring from the beginning of the
RS complex to the visual return of the T-wave to the
soelectric line. Where the T-wave was complicated by a
-wave, the end of the T-wave was defined as the nadir
etween the T- and U-wave (11). The QT intervals were
orrected for heart rate (QTc) (12). The QTD for each
CG recording was defined as the difference between the
ongest and shortest measured QT (13). Assessment of the
CG was done during the intrinsic rhythm at baseline and
uring biventricular pacing at follow-up.
Two-dimensional echocardiography was performed using
he VIVID System 5 (General Electric, Milwaukee, Wiscon-
in). Standard left parasternal long-axis and short-axis, and
pical, four-, five-, and two-chamber views were obtained.
igital images were stored for offline analysis (EchoPAC,
ingmed-General Electric). The LV volumes were esti-
ated through Simpson’s equation by planimetry of apical
our-chamber views. The frame at the beginning of the
RS complex was used to estimate left ventricular end-
iastolic volume (LVEDV), whereas the frame with the
mallest ventricular area just before mitral valve opening was
sed to estimate left ventricular end-systolic volume
LVESV). We derived LVEF from end-systolic volume and
nd-diastolic volume using standard formulae.
tatistical analysis. Continuous variables are expressed as
ean  SEM for normally distributed variables. Compar-
sons between normally distributed continuous variables
ere made using the Student t test. The Mann-Whitney U
est was used for analysis of non-normally distributed data.
he Cox proportional-hazards model was used to examine
he risk of MAE in relation to baseline QTc and QTD as
ell as subsequent changes in these parameters (QTc and
QTD) between baseline and the first clinic review at 48
ays. Variables showing significant group differences were
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QT Dispersion in CRT June 20, 2006:2486–92ntered into multivariate regression models. The relation-
hip between QTD and survival was explored using
aplan-Meier survival analysis. Differences in survival
urves between the groups were assessed using the log-rank
Mantel-Cox) test. Differences between categorical vari-
bles were analysed using the chi-square test. Statistical
nalyses were performed using Statview (Cary, North Caro-
ina). A two-tailed p value of 0.05 was considered statis-
ically significant.
ESULTS
he characteristics of the study group are shown in Table 1.
ompared with the no-MAE group, the MAE group had
higher NYHA functional class (p  0.006), longer QRS
omplexes (p  0.034) as well as higher LVESV (p 
.010) and LVEDV (p  0.022), and a lower LVEF (p 
.025). There were no differences in heart rate before CRT.
Table 1. Characteristics of the Study Group
All
n 75
Age, yrs 67.8  1.4
Gender, male (%) 58 (77)
NYHA functional class, n (%)
III 46 (61)
IV 29 (39)
6-min walk test 240.3  12.
Quality-of-life score 55.7  2.2
Etiology, n (%)
Coronary heart disease 53 (71)
Dilated cardiomyopathy 22 (29)
Systolic blood pressure, mm Hg 116.1  2.6
Diastolic blood pressure, mm Hg 69.5  12.
Serum creatinine, mol/l 122.5  3.5
Comorbidity
Diabetes mellitus 8 (11)
Hypertension 20 (27)
Medication, n (%)
Loop diuretics 68 (91)
ACE-I or ARB 66 (88)
Beta-blockers 39 (52)
Spironolactone 37 (49)
Amiodarone 15 (20)
ECG variables
Rate, beats/min 74.4  2.0
Rhythm, n (%)
Sinus rhythm 56 (75)
Atrial fibrillation 19 (25)
QRS duration, ms 156.9  2.5
QTc interval, ms 484.7  5.3
QT dispersion, ms 47.3  3.1
Tpeak-end interval, ms 113.9  3.7
Capture threshold, V† 1.16  0.1
Echocardiographic variables
LVEF, % 32  1.0
LVEDV 200.7  10.
LVESV 142.2  9.4
*Differences between the group with major arrhythmic event
implantation, at a pulse width of 0.5 ms. Continuous variab
ACE-I  angiotensin converting enzyme inhibitors; AR
end-diastolic volume; LVEF  left ventricular ejection fraction;
significant; NYHA  New York Heart Association class; QTc eart rate increased by 6.58 beats/min at follow-up (p 
.0023), but there was no difference between the MAE and
o-MAE groups. No significant change in the ventricular
esponse was observed in patients with atrial fibrillation
83.1  5.3 beats/min vs. 87.8  3.4 beats/min, p  NS).
After a follow-up period of 807 days (range 93 to 1,543
ays), no differences from baseline in six-min walk test,
uality of life, or NYHA functional class were observed in
atients with MAE and no-MAE (Table 2). Responders,
efined as patients who exhibited an increase in 6-min walk
est distance above baseline at follow-up, were 7 (64%) in
he MAE group and 41 (64%) in the non-MAE group
NS). By the end of the follow-up period, 11 patients had a
AE: 10 patients died suddenly and 1 was successfully
esuscitated from ventricular fibrillation. The MAE oc-
urred at a mean of 515 days (range 93 to 917 days) after
elivery of CRT.
MAE No MAE p Value*
11 64
69.3  3.1 67.6  1.5 NS
11 (100) 47 (73) 0.052
4 (36) 42 (66) 0.006
7 (64) 22 (34) 0.006
235.1  31.8 241.2  14.2 NS
55.1  4.9 55.8  2.5 NS
8 (73) 45 (70) NS
3 (27) 19 (30) NS
109.4  5.2 117.3  3.0 NS
67.3  4.1 69.5  1.8 NS
134.0  7.3 120.5  3.9 NS
1 (9) 7 (11) NS
2 (18) 18 (28) NS
10 (91) 58 (91) NS
9 (82) 57 (89) NS
2 (18) 23 (36) NS
5 (45) 31 (49) NS
2 (18) 13 (20) NS
74.7  3.4 74.4  2.3 NS
8 (73) 48 (75) NS
3 (27) 16 (25) NS
169.7  6.1 154.7  2.7 0.034
482.6  14.2 485.0  5.8 NS
32.7  2.9 49.8  3.5 0.050
105.0  10.4 115.8  3.9 NS
0.97  0.18 1.20  0.13 NS
25.1  0.4 33.0  0.01 0.025
259.3  36.7 191.1  10.2 0.022
201.2  36.9 132.6  8.7 0.010
E) and the group without (no MAE); †capture threshold at
expressed as mean  SEM.
ngiotensin II receptor blockers; LVEDV  left ventricular9
7
5
s (MA
les are
B  aLVESV  left ventricular end-systolic volume; NS  not
rate-corrected QT interval.
M
A
s
i
(
d
M
e
3
Q
m
i
e
e
t
b
f
t
e
b
d
i
i
r
w
t
m
h
C
Q
T
ts (MA
F
p
M
2489JACC Vol. 47, No. 12, 2006 Chalil et al.
June 20, 2006:2486–92 QT Dispersion in CRTAs shown in Figure 1, comparison of the groups with
AE and no MAE revealed no differences in baseline QTc.
lthough QTD was lower in the MAE group, this was not
tatistically significant. In the whole study sample, no changes
n QTc (484.7 5.3 ms vs. 491.4 5.1 ms, pNS) or QTD
47.3  3.1 ms vs. 49.9  3.7 ms, p  NS) were observed 48
ays after implantation. When patients were grouped into
AE and no-MAE groups, however, significant differences
merged in the change at follow-up in QTc (QTc, MAE:
5.9  14.2 ms, no MAE: 0.52  6.0 ms; p  0.0323) and
TD (QTD, MAE: 46.4 13.5 ms, no MAE5.1 4.1
s, p 0.0001). In the whole-study sample, 47% exhibited an
ncrease in QTD above baseline at follow-up, whereas 53%
xhibited a decrease. The MAE occurred in 29% of patients
xhibiting an increase in QTD above baseline and in 3% of
hose exhibiting a decrease (p  0.0017). No differences in
aseline QTc or QTD or changes in these measures at
Table 2. Changes in Clinical Variables During
All Patients
n 75
NYHA functional class 1.3  0.10
6-min walk test, m 71.6  12.5
Quality-of-life score 20.0  2.6
*Differences between the group with major arrhythmic even
NYHA  New York Heart Association.
igure 1. Box plots of baseline QT interval (QTc) duration and QT disper
acemaker implantation. The five solid horizontal lines represent the 10th, 25t
AE  major arrhythmic events.ollow-up emerged when patients were grouped according
o medical therapy with diuretics, angiotensin-converting
nzyme inhibitors/angiotensin receptor antagonists, beta-
lockers, or amiodarone. As shown in Figure 2, QRS
uration at baseline correlated positively with QTc follow-
ng implantation, but not with QTD.
At baseline, there was no group difference in the Tpeak-end
nterval. Following implantation, however, there was an overall
eduction in the Tpeak-end interval (16.5  5.0 ms for the
hole cohort), which was more marked in the no-MAE group
han in the MAE group (20.0  5.4 ms and 1.5  12.8
s, respectively, p 0.047). Changes in the Tpeak-end interval,
owever, failed to emerge as a significant predictor of MAE in
ox proportional hazards analyses.
In a Cox proportional hazards analyses, baseline QTc or
TD did not emerge as predictors of MAE. As shown in
able 3, QTD emerged as a significant predictor of MAE
Follow-Up Period
MAE No MAE p Value*
11 64
.18  0.26 1.32  0.11 NS
9.8  35.2 71.9  13.4 NS
3.0  7.3 21.3  2.7 NS
E) and the group without (no MAE).
(QTD) and their changes from baseline to 48 days following biventricularthe
1
6
1sion
h, 50th, 75th, and 90th percentiles of each variable, from bottom to top.
i
L
t
t
s
m
f
D
W
H
p
p
p
i
f
w
Q
L
e
p
d
d
fi
c
o
a
a
w
t
Q
d
i
l
h
w
s
f
e
BT
A
M
M
M
M
L
f
nges
F
d
2490 Chalil et al. JACC Vol. 47, No. 12, 2006
QT Dispersion in CRT June 20, 2006:2486–92ndependent of QTc as well as baseline QRS duration,
VEF, and LVEDV. For Kaplan-Meier survival analyses,
he pooled sample was stratified according to varying
hresholds of QTD. The most significant difference in
urvival curves was observed when patients were dichoto-
ized according to whether QTD increased or decreased
rom baseline values (Fig. 3).
ISCUSSION
e have shown that in patients with moderate-to-severe
F undergoing CRT, QTc and QTD at baseline are not
redictors of MAE. The novel finding of this study is that
acing-induced increases in QTc and QTD are strong
redictors of subsequent MAE in such patients. An increase
n QTD above baseline values confers the greatest risk of
uture MAE. As expected from other studies (14), patients
ith MAE had a worse NYHA functional class, longer
RS complexes, a lower LVEF, and higher LVEDV and
VESV. The relationship between QTD and MAE, how-
ver, was independent of these variables.
able 3. Cox Proportional Hazards Models Adopting Major
rrhythmic Events as the Dependent Variable
Chi-Square p Value
Likelihood
Ratio p Value
odel A
QTD 17.5 0.0001 13.7 0.0002
odel B
QTD 10.7 0.0011 16.0 0.0011
QTc 0.18 NS
QRS duration 1.24 NS
odel C
QTD 10.2 0.0014 25.1 0.0001
QTc 1.32 NS
QRS duration 1.51 NS
Baseline LVEF 6.67 0.0098
odel D
QTD 11.4 0.0008 22.2 0.0002
QTc 2.12 NS
QRS duration 0.07 NS
Baseline LVEDV 6.24 0.0125
Figure 2. Regression analyses of QRS duration in relation to chaVEDV  left ventricular end-diastolic volume; LVEF  left ventricular ejection
raction; QTc and QTD  change from baseline in QTc and QT dispersion.
m
iAlthough QTD has been shown to predict mortality in
opulation-based studies (15) and in patients with myocar-
ial infarction (16) and HF (17), it has been generally
isappointing as a predictor of arrhythmic events. Our
ndings of a pacing-induced increase in QTc and QTD is
onsistent with experimental studies showing that reversal
f myocardial depolarization through epicardial stimulation,
s occurs in LV pacing via the coronary sinus, promotes
rrhythmogenesis. Using arterially perfused canine LV
edge preparations, Fish et al. (5) observed that reversing
he direction of LV wall activation leads to an increase in
Tcduration. This has been linked to increased transmural
ispersion of repolarization resulting from earlier repolar-
zation of the epicardium and delayed activation and repo-
arization of the midmyocardial M cells (5). Similar findings
ave been reported in clinical studies. In a series of patients
ith HF undergoing CRT, Medina-Ravell et al. (3) ob-
erved increases in the QT and JT interval durations
ollowing LV epicardial and BiVP, but not with isolated RV
ndocardial pacing.
On the other hand, several studies have suggested that
iVP exerts an antiarrhythmic effect. In a randomized
from baseline in QT interval (QTc) and QT dispersion (QTD).
igure 3. Kaplan-Meier survival curves according to change in QT
ispersion (QTD) from baseline to 48 days following biventricular pace-
aker implantation. Dotted line  decrease in QTD; solid line 
ncrease in QTD.
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June 20, 2006:2486–92 QT Dispersion in CRTrossover study using 24-h Holter monitoring, Paul et al.
18) showed that BiVP significantly reduced ventricular
ctopic counts when compared to isolated RV pacing. In a
ohort of participants of the Ventak trial (single-blinded,
andomized, crossover study of BiVP plus ICD for three
onths, followed by three months of no pacing plus ICD),
iggins et al. (19) observed a lower frequency of antitachy-
ardia therapies during BiVP compared to the periods of no
acing (16% vs. 34% respectively; p 0.04). In contrast, the
eta-analysis of CRT trials of Bradley et al. (2) showed that
hereas CRT significantly reduced death from progressive
F, CRT tended to promote sudden, presumed arrhyth-
ic, deaths. In our study, 47% of patients exhibited a
acing-induced increase in QTD above baseline, whereas
3% exhibited a decrease. This raises the possibility that
iVP has differential effects on the arrhythmogenic
ubstrate, antiarrhythmic in some and arrhythmogenic in
thers. It is noteworthy that other treatments, such as class
antiarrhythmic agents, also have a differential effect on the
rrhythmogenic substrate (20). In contrast, a study of 25
atients using a high-resolution 65-lead surface ECG (21) has
hown that BiVP leads to a reduction in QTD from 114 22
s (sinus rhythm) to 90  12 ms. The standard deviations
uoted in this study, however, raise the possibility that some
atients may have exhibited an increase in QTD.
With regard to the Tpeak-end interval, Berger et al. (21)
ound that the biventricular pacing leads to an overall
eduction of 81  13.8 ms (mean  SD) compared to sinus
hythm. It would appear from these standard deviations that
reduction in Tpeak-end interval was not found in all
atients. We found that the reduction was significantly less
ronounced in the MAE group. The discrepancies between
ur findings and those of Berger et al. (21) may relate to the
ifferent methodologies used to collect ECG data or to the
ime difference between ECG recordings following pacing.
he salient finding from our study is that CRT has a
ifferential effect on the Tpeak-end interval and that this is
elated to the development of MAE.
These findings may be relevant to the observation from
he CARE-HF study that CRT reduces all-cause mortality
ut not sudden cardiac death (1). This raises the possibility
hat the favorable effects on mortality are negated by an
ncrease in the risk of death from non-HF causes, among
hich are fatal arrhythmias. Whether pacing-induced ar-
hythmias in susceptible patients could be responsible for
he apparent dilution of the survival benefit from CRT
equires further investigation.
Examination of secondary end point data from the
omparison of Medical Therapy, Pacing and Defibrillation
n Heart Failure (COMPANION) trial (14) shows that
ll-cause mortality was lower in the pacemaker and
acemaker-defibrillator groups than in the pharmacological
roup after 12 months (15% and 12% compared to 19%,
 0.059 and p  0.003, respectively). Interestingly, the
urvival curves for all-cause mortality begin to separate
etween day 270 and 360 after randomization. This suggestshat the benefit from ICD therapy is late and is in keeping with
ur data showing that the risk of MAE in CRT patients who
eveloped pacing-induced increases in QTD also becomes
pparent late after delivery of CRT, between day 350 and 450
fter implantation.
tudy limitations. This study has several limitations. First,
t is small and observational. A relatively long follow-up
eriod, however, has yielded sufficient MAE to achieve
tatistical significance in survival analyses. Second, the
hortcomings of the standard definition of sudden cardiac
eath used in this study are well recognized. Thirdly,
easurement of the QTccan be inaccurate. Manual mea-
urement of QTc, however, is as reproducible as automatic
easurement (10). We have adopted the horizontal plane
eads V1 to V6 because these are more likely to reflect real
ocal activity (10).
onclusions. Our findings have emerged in the context
hat CRT delays death from progressive HF, but not from
ll causes. We have shown that CRT has differential effects
n QTD, leading to a reduction in some patients and to an
ncrease in others. Patients who exhibit an increase in QTD
ollowing CRT are at increased risk of MAE compared with
hose who exhibit a decrease. Further studies are needed to
etermine whether evaluation of QTD at the time of
iventricular pacemaker implantation can be used to risk-
tratify patients for the preferential use of CRT with ICD
ackup.
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